In recent years, drug pricing has been under extreme pressure due to the rising costs of healthcare and the political environment. This is taking a toll on both branded drug manufacturers – but even more on generics manufacturers, who have lower margins and are suffering from an increasing degree of competitive pressure. In this environment, our client was looking to streamline their operations into a source of competitive advantage by evaluating their overall network strategy – resizing and reshaping their network for the new realities of their business. Megan DeFauw, a Principal from our Dallas office, will lead this virtual session walking through her specific experience on this case, as well as an overview of BCG’s work in healthcare operations overall.
Log-in instructions will be sent to you 1-2 hours prior to the event